{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:48:33Z","timestamp":1778809713743,"version":"3.51.4"},"reference-count":179,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Genitourinary (GU) malignancies are common and associated with significant morbidity and mortality. In patients with localized GU cancers, surgical resection or definitive radiation remain the mainstays of treatment. Despite definitive treatment, many patients with high-risk localized disease experience recurrence. There is growing interest in using neoadjuvant immunotherapy to improve outcomes. This narrative review summarizes the current evidence for neoadjuvant immunotherapy in patients with localized high-risk GU cancers including renal cell carcinoma, urothelial carcinoma, prostate cancer, penile squamous cell carcinoma, and testicular germ cell tumors. We also discuss ongoing clinical trials and candidate biomarkers to optimize patient selection and improve treatment outcomes.<\/jats:p>","DOI":"10.3390\/cancers16244127","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T08:40:10Z","timestamp":1733820010000},"page":"4127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4603-376X","authenticated-orcid":false,"given":"Adam","family":"Khorasanchi","sequence":"first","affiliation":[{"name":"Division of Hospital Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karan","family":"Jatwani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingbin","family":"Meng","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0485-8031","authenticated-orcid":false,"given":"Katharine A.","family":"Collier","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6980-4777","authenticated-orcid":false,"given":"Debasish","family":"Sundi","sequence":"additional","affiliation":[{"name":"Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Dason","sequence":"additional","affiliation":[{"name":"Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Singer","sequence":"additional","affiliation":[{"name":"Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmesh","family":"Gopalakrishnan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Mortazavi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurkamal","family":"Chatta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5209-9247","authenticated-orcid":false,"given":"Yuanquan","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","unstructured":"de Bono, J., Gillessen, S., Mehra, N., and Loriot, Y. (2020). Genitourinary Tract Tumours: Essentials for Clinicians, ESMO Press. [2nd ed.]."},{"key":"ref_3","unstructured":"Motzer, R.J., Memorial Sloan Kettering Cancer Center, \u00de., Jonasch, E., Agarwal, N., Alva, A., Bagshaw, H., Baine, M., Beckermann, K., Carlo, M.I., and Memorial Sloan Kettering Cancer Center Toni Choueiri, M.K. (2024). NCCN Guidelines Version 1.2025 Kidney Cancer Continue NCCN Guidelines Panel Disclosures, NCCN."},{"key":"ref_4","unstructured":"Flaig, T.W., Spiess, P.E., Chair, V., Abern, M., Agarwal, N., Chan, K., Chang, S.S., Chang, P., Greenberg, R.E., and Fox Chase Cancer Center Khurshid Guru, W.A. (2024). NCCN Guidelines Version 4.2024 Bladder Cancer, NCCN."},{"key":"ref_5","unstructured":"Schaeffer, E.M., Lurie, R.H., Adra, N., An, Y., Bitting, R., Chapin, B., Cheng, H.H., Victor, A.D., Desai, N., and Dorff, T. (2024). NCCN Guidelines Version 4.2024 Prostate Cancer, NCCN."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1200\/EDBK_279459","article-title":"Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions","volume":"40","author":"McKay","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00345-020-03550-z","article-title":"Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma","volume":"39","author":"Martini","year":"2021","journal-title":"World J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"ref_10","first-page":"435.e417","article-title":"Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times","volume":"39","author":"McCaw","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100785","DOI":"10.1016\/j.xcrm.2022.100785","article-title":"Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study","volume":"3","author":"Hu","year":"2022","journal-title":"Cell Rep. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/jnci\/djaa217","article-title":"Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?","volume":"113","author":"Bilusic","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Apolo, A.B., Ballman, K.V., Sonpavde, G., Berg, S., Kim, W.Y., Parikh, R., Teo, M.Y., Sweis, R.F., Geynisman, D.M., and Grivas, P. (2024). Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2401726"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Blank, C.U., Lucas, M.W., Scolyer, R.A., van de Wiel, B.A., Menzies, A.M., Lopez-Yurda, M., Hoeijmakers, L.L., Saw, R.P.M., Lijnsvelt, J.M., and Maher, N.G. (2024). Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2402604"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e009722","DOI":"10.1136\/jitc-2024-009722","article-title":"Immune checkpoint blockade: Timing is everything","volume":"12","author":"Sinicrope","year":"2024","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Khorasanchi, A., Goodstein, T., Dason, S., Singer, E.A., Zimmerman, D., and Yang, Y. (2023). Perioperative systemic therapy in high-risk renal cell carcinoma following nephrectomy: A narrative review. Transl. Cancer Res.","DOI":"10.21037\/tcr-24-16"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-022-00710-5","article-title":"Perioperative immunotherapy for renal cell carcinoma: Looking beyond the data","volume":"20","author":"Labaki","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102528","DOI":"10.1016\/j.ctrv.2023.102528","article-title":"Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario","volume":"115","author":"Ciccarese","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Khaleel, S., Jiang, S., Kotecha, R.R., and Hakimi, A.A. (2022). Neoadjuvant Systemic Therapy in Localized and Locally Advanced Renal Cell Carcinoma. Front. Urol., 2.","DOI":"10.3389\/fruro.2022.864778"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Mattila, K.E., Vainio, P., and Jaakkola, P.M. (2022). Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy. Cancers, 14.","DOI":"10.3390\/cancers14010239"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-022-01683-6","article-title":"First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?","volume":"82","author":"Adashek","year":"2022","journal-title":"Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ucl.2023.01.011","article-title":"The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer","volume":"50","author":"Leow","year":"2023","journal-title":"Urol. Clin. N. Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ucl.2020.04.010","article-title":"Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma","volume":"47","author":"Westerman","year":"2020","journal-title":"Urol. Clin. N. Am."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.eururo.2019.12.018","article-title":"Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?","volume":"77","author":"Pignot","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.euo.2021.11.004","article-title":"Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor\u2013based Dual Combination Therapy","volume":"5","author":"Graafland","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_32","first-page":"3","article-title":"Chances, risks and limitations of neoadjuvant therapy in surgical oncology","volume":"1","author":"Lordick","year":"2016","journal-title":"Innov. Surg. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.eururo.2022.02.013","article-title":"Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges into Opportunities","volume":"81","author":"Marandino","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euo.2021.04.002","article-title":"Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma","volume":"5","author":"Gorin","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2022.01.043","article-title":"Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy","volume":"81","author":"Carlo","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2217\/fon-2018-0951","article-title":"The Future of Perioperative Therapy in Advanced Renal Cell Carcinoma: How Can We Prosper?","volume":"15","author":"Patel","year":"2019","journal-title":"Future Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","article-title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): An open-label, randomised, phase 3 study","volume":"25","author":"Allaf","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(24)00268-7","article-title":"Perioperative immunotherapy in renal cell carcinoma","volume":"25","author":"Borchiellini","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1200\/JCO.2020.38.15_suppl.5021","article-title":"A phase Ib trial of neoadjuvant\/adjuvant durvalumab +\/- tremelimumab in locally advanced renal cell carcinoma (RCC)","volume":"38","author":"Ornstein","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/s41467-023-38342-7","article-title":"Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma","volume":"14","author":"Karam","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2024.42.4_suppl.420","article-title":"A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC)","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e008475","DOI":"10.1136\/jitc-2023-008475","article-title":"Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: A single-arm, phase II trial","volume":"12","author":"Huang","year":"2024","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2022.40.6_suppl.289","article-title":"Efficacy, safety, and biomarker analysis of neoadjuvant avelumab\/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx)","volume":"40","author":"Bex","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.euf.2020.01.007","article-title":"Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives","volume":"6","author":"Gakis","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","article-title":"Randomized Phase III Trial of High\u2013Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924","volume":"19","author":"Sternberg","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ikarashi, D., Kitano, S., Tsuyukubo, T., Yamashita, M., Matsuura, T., Maekawa, S., Kato, R., Kato, Y., Kanehira, M., and Takata, R. (2024). Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-51273-7"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.urology.2024.04.034","article-title":"Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen","volume":"188","author":"Eule","year":"2024","journal-title":"Urology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.juro.2017.12.062","article-title":"Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy","volume":"199","author":"Zargar","year":"2018","journal-title":"J. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","article-title":"Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG\/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","article-title":"Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity","volume":"32","author":"Plimack","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000463389","article-title":"Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer","volume":"93","author":"Puntus","year":"2017","journal-title":"Oncology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1002\/cncr.24466","article-title":"Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy","volume":"115","author":"Sonpavde","year":"2009","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdx692","article-title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive\/Advanced Cancer of the Urothelium (RISC)","volume":"29","author":"Bamias","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ogbuji, V., Paster, I.C., Recio-Boiles, A., Carew, J.S., Nawrocki, S.T., and Chipollini, J. (2023). Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?. Cancers, 16.","DOI":"10.3390\/cancers16010131"},{"key":"ref_58","unstructured":"Klaassen, Z. (2024, September 01). EAU 2024: Extended Follow-Up from CheckMate 274 Including the First Report of Overall Survival Outcomes. Available online: https:\/\/www.urotoday.com\/conference-highlights\/eau-2024\/eau-2024-bladder-cancer\/150967-eau-2024-extended-follow-up-from-checkmate-274-including-the-first-report-of-overall-survival-outcomes.html."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-18-2641","article-title":"The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment","volume":"25","author":"Hoefsmit","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.euo.2020.11.010","article-title":"Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial","volume":"4","author":"Szabados","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2022.40.16_suppl.4517","article-title":"Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial","volume":"40","author":"Carnot","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/JCO.2021.39.15_suppl.4518","article-title":"PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)","volume":"39","author":"Grivas","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial","volume":"40","author":"Funt","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: The NABUCCO trial","volume":"26","author":"Silina","year":"2020","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2020.38.15_suppl.5012","article-title":"DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature","volume":"38","author":"Grande","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: A phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2023.41.6_suppl.448","article-title":"HCRN GU14-188: Phase Ib\/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer","volume":"41","author":"Brown","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1200\/JCO.2020.38.6_suppl.499","article-title":"Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin\/gemcitabine (Cis\/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06\/17)","volume":"38","author":"Cathomas","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S1202","DOI":"10.1016\/j.annonc.2023.09.1013","article-title":"2364MO Durvalumab (D) +\/\u2212 tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial","volume":"34","author":"Thibault","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Powles, T., Catto, J.W.F., Galsky, M.D., Al-Ahmadie, H., Meeks, J.J., Nishiyama, H., Vu, T.Q., Antonuzzo, L., Wiechno, P., and Atduev, V. (2024). Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N. Engl. J. Med., 1\u201314.","DOI":"10.1056\/NEJMoa2408154"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.eururo.2019.12.019","article-title":"Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial","volume":"77","author":"Briganti","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_81","unstructured":"Grande, E., Guerrero, F., Puente, J., Galante, I., Duran, I., Dominguez, M., Alonso Gordoa, T., Burgos, J., Font, A., and Pinto, A. (2022). Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers, Springer International Publishing."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.2011.39.1300","article-title":"Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer","volume":"30","author":"Nelson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/EDBK_351033","article-title":"Best Approaches and Updates for Prostate Cancer Biochemical Recurrence","volume":"42","author":"Simon","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4103\/iju.IJU_115_20","article-title":"Neoadjuvant therapy in high-risk prostate cancer","volume":"36","author":"Ashrafi","year":"2020","journal-title":"Indian J. Urol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11934-016-0592-4","article-title":"Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy","volume":"17","author":"Pietzak","year":"2016","journal-title":"Curr. Urol. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Yanagisawa, T., Rajwa, P., Quhal, F., Kawada, T., Bekku, K., Laukhtina, E., Deimling, M.v., Chlosta, M., Karakiewicz, P.I., and Kimura, T. (2023). Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review. J. Pers. Med., 13.","DOI":"10.3390\/jpm13040641"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"TPS285","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS285","article-title":"PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC)","volume":"40","author":"Kibel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_91","first-page":"210","article-title":"Prostate cancer immunotherapy: A review of recent advancements with novel treatment methods and efficacy","volume":"10","author":"Wang","year":"2022","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e1644109","DOI":"10.1080\/2162402X.2019.1644109","article-title":"Immune checkpoint inhibitors in mCRPC rationales, challenges and perspectives","volume":"8","author":"Taghizadeh","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wang, L., Pan, S., Zhu, B., Yu, Z., and Wang, W. (2021). Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer. BMC Urol., 21.","DOI":"10.1186\/s12894-021-00795-7"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"108114","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Park, K., Veena, M.S., and Shin, D.S. (2022). Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.830208"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Yaseen, M.M., Abuharfeil, N.M., Darmani, H., and Daoud, A. (2020). Mechanisms of immune suppression by myeloid-derived suppressor cells: The role of interleukin-10 as a key immunoregulatory cytokine. Open Biol., 10.","DOI":"10.1098\/rsob.200111"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Movassaghi, M., Chung, R., Anderson, C.B., Stein, M., Saenger, Y., and Faiena, I. (2021). Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances. Cancers, 13.","DOI":"10.3390\/cancers13194757"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-24-0060","article-title":"Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer","volume":"30","author":"Dallos","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhang, H., Ye, L., Yu, X., Jin, K., and Wu, W. (2022). Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.956984"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Li, Q., Liu, T., and Ding, Z. (2022). Neoadjuvant immunotherapy for resectable esophageal cancer: A review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1051841"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00262-012-1317-2","article-title":"Sipuleucel-T immune parameters correlate with survival: An analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer","volume":"62","author":"Sheikh","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e1486953","DOI":"10.1080\/2162402X.2018.1486953","article-title":"Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer","volume":"8","author":"Hagihara","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_105","first-page":"687","article-title":"Phase II Trial of Neoadjuvant Docetaxel and CG1940\/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk Clinically Localized Prostate Cancer","volume":"18","author":"Vuky","year":"2013","journal-title":"OncoImmunology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","article-title":"T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer","volume":"26","author":"Obradovic","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_107","unstructured":"(2024, September 01). Study Details. Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00577356?a=2."},{"key":"ref_108","unstructured":"(2024, September 01). Study Details. Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00004050."},{"key":"ref_109","unstructured":"(2024, September 01). Study Details. Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04020094."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41585-022-00617-x","article-title":"Immune-based therapies in penile cancer","volume":"19","author":"Joshi","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40487-020-00135-z","article-title":"Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature","volume":"9","author":"Stecca","year":"2021","journal-title":"Oncol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.2021.39.6_suppl.5","article-title":"Prognostic significance of human papilloma virus (HPV) in penile cancer: A National Cancer Database (NCDB) study","volume":"39","author":"Chennamadhavuni","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10637-021-01100-x","article-title":"Pembrolizumab for advanced penile cancer: A case series from a phase II basket trial","volume":"39","author":"Hahn","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/JCO.2022.40.6_suppl.003","article-title":"Clinical results of PERICLES: A phase II trial investigating atezolizumab +\/- radiotherapy for advanced squamous cell carcinoma of the penis","volume":"40","author":"Bekers","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/jnci\/djad155","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: Report from the Global Society of Rare Genitourinary Tumors","volume":"115","author":"Nassar","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"67","DOI":"10.12703\/r\/10-67","article-title":"Recent advances in testicular germ cell tumours","volume":"10","author":"Mele","year":"2021","journal-title":"Fac. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"573977","DOI":"10.3389\/fonc.2020.573977","article-title":"Immunotherapy in Testicular Germ Cell Tumors","volume":"10","author":"Kalavska","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: A Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/onco.13682","article-title":"Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors","volume":"26","author":"Tsimberidou","year":"2021","journal-title":"Oncologist"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Labadie, B.W., Balar, A.V., and Luke, J.J. (2021). Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 13.","DOI":"10.3390\/cancers13215415"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s10637-022-01276-w","article-title":"A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors","volume":"40","author":"Adra","year":"2022","journal-title":"Investig. New Drugs"},{"key":"ref_124","unstructured":"(2024, September 01). Study Details. Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-Positive Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05262530."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: The phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"732.e9","DOI":"10.1016\/j.urolonc.2021.03.004","article-title":"Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer","volume":"39","author":"Khaki","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2024.2924","article-title":"Neoadjuvant Immunotherapy-From Trials to Practice","volume":"10","author":"Mittendorf","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s12325-022-02365-1","article-title":"Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States","volume":"40","author":"Huang","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Tian, W., Niu, L., Wang, Z., Lu, R., Xiao, G., Deng, F., Tanzhu, G., and Zhou, R. (2023). Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1268070"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Proietti, F., Flammia, R.S., Licari, L.C., Bologna, E., Bove, A.M., Brassetti, A., Tuderti, G., Mastroianni, R., Tufano, A., and Simone, G. (2024). Impacts of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients with Bladder Cancer Treated with Radical Cystectomy: A Single High-Volume Center Experience. J. Pers. Med., 14.","DOI":"10.3390\/jpm14020212"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bju.12585","article-title":"Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity","volume":"114","author":"Johnson","year":"2014","journal-title":"BJU Int."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.eururo.2014.01.014","article-title":"The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: A population-based study","volume":"66","author":"Gandaglia","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Riveros, C., Elshafei, A., Chalfant, V., Alam, U., and Balaji, K.C. (2022). Complications after neoadjuvant chemotherapy and radical cystectomy for patients with bladder cancer: A propensity score matched analysis. Can. Urol. Assoc. J.","DOI":"10.5489\/cuaj.7952"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00345-018-2584-0","article-title":"Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy","volume":"37","author":"Milenkovic","year":"2019","journal-title":"World J. Urol."},{"key":"ref_137","first-page":"939","article-title":"Bladder cancer in the elderly patient: Challenges and solutions","volume":"10","author":"Guancial","year":"2015","journal-title":"Clin. Interv. Aging"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"ref_139","unstructured":"(2024, September 01). Study Details. A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04028245."},{"key":"ref_140","unstructured":"(2024, September 01). Study Details. Neoadjuvant Study With Combination Immuno-Oncology for Primary Clear Cell Renal Cell Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05148546?tab=results."},{"key":"ref_141","unstructured":"(2024, September 01). Study Details. NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05024318."},{"key":"ref_142","unstructured":"(2024, September 01). Study Details. Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05319015."},{"key":"ref_143","unstructured":"(2024, September 01). Study Details. Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05733715."},{"key":"ref_144","unstructured":"(2024, September 01). Study Details. Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06138496?tab=results."},{"key":"ref_145","unstructured":"(2024, September 01). Study Details. Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-Invasive Bladder Cancer Patients With FGFR Gene Alterations, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06511648."},{"key":"ref_146","unstructured":"(2024, September 01). Study Details. Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866\/KEYNOTE-866), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03924856."},{"key":"ref_147","unstructured":"(2024, September 01). Study Details. Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15 KEYNOTE-B15 EV-304), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04700124."},{"key":"ref_148","unstructured":"(2024, September 01). Study Details. Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (MK-3475-905\/KEYNOTE-905\/EV-303), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03924895."},{"key":"ref_149","unstructured":"(2024, September 01). Study Details. PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02933255."},{"key":"ref_150","unstructured":"(2024, September 01). Study Details. Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-Metastatic Castrate-sensitive Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06555796."},{"key":"ref_151","unstructured":"(2024, September 01). Study Details Non-Fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04301414."},{"key":"ref_152","unstructured":"(2024, September 01). Study Details. Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03821246."},{"key":"ref_153","unstructured":"(2024, September 01). Study Details. Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04009967."},{"key":"ref_154","unstructured":"(2024, September 01). Study Details. Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03899987?a=3."},{"key":"ref_155","unstructured":"(2024, September 01). Study Details. TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04475016."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_157","unstructured":"(2024, September 01). Study Details. Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-Based Therapy, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06263153."},{"key":"ref_158","unstructured":"(2024, September 01). Study Details. A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle Invasive Bladder Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03661320."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.trecan.2023.07.011","article-title":"Genitourinary cancer neoadjuvant therapies: Current and future approaches","volume":"9","author":"Nair","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_160","unstructured":"(2024, September 01). Study Details. Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04960709."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"TPS579","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579","article-title":"A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA)","volume":"40","author":"Powles","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Kalina, J., Neilson, D., Comber, A., Rauw, J., Alexander, A., Vergidis, J., and Lum, J. (2017). Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers, 9.","DOI":"10.3390\/cancers9020013"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Ukleja, J., Kusaka, E., and Miyamoto, D.T. (2021). Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.663852"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"TPS352","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS352","article-title":"A randomized phase I\/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial)","volume":"42","author":"Krafft","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_165","unstructured":"(2024, September 01). Study Details. Pembrolizumab Combined With Cisplatin-Based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04224740."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e430734","DOI":"10.1200\/EDBK_430734","article-title":"Update on Biomarkers in Renal Cell Carcinoma","volume":"44","author":"Saliby","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ccell.2024.04.003","article-title":"Molecular subtypes as potential biomarkers in renal cell carcinoma","volume":"42","author":"Agarwal","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Seema, M., Jansen, C.S., Jani, Y., Evans, S., Zhuang, T.Z., Brown, J., Nazha, B., Master, V., and Bilen, M.A. (2024). The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers. Biomark. Insights, 19.","DOI":"10.1177\/11772719241254179"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2020.06.021","article-title":"Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial","volume":"79","author":"Rini","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41591-018-0235-z","article-title":"Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2024.42.16_suppl.4506","article-title":"Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection","volume":"42","author":"Albiges","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-018-0314-1","article-title":"Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond","volume":"6","author":"Zhu","year":"2018","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study","volume":"31","author":"Bandini","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"17588359231192402","DOI":"10.1177\/17588359231192402","article-title":"Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer","volume":"15","author":"Parent","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12943-024-01945-9","article-title":"Multi-cohort validation of Ascore: An anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer","volume":"23","author":"Xie","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/PO.19.00399","article-title":"CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors","volume":"4","author":"Antonarakis","year":"2020","journal-title":"JCO Precis. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:51:26Z","timestamp":1760115086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":179,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16244127"],"URL":"https:\/\/doi.org\/10.3390\/cancers16244127","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}